Windtree Therapeutics

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Windtree Therapeutics Inc (NASDAQ: WINT) increased by 36.36% on Friday, June 4. This is why it happened.

WINT Stock Price: 36.36% Increase Explanation

Vinco Ventures

Future FinTech Group

Meme penny stocks are in focus right now, what are they, and which small-caps are investors watching? The post Meme Penny Stocks, What Are They, and 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Meme Penny Stocks, What Are They, and 3 to Watch Right Now

Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target. Windtree Therapeutics is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases.

Why Windtree Therapeutics Stock Is Moving Today

WARRINGTON, Pa., May 13, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.

Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 19, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT).

Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent

Agile Therapeutics

Checkmate Pharmaceuticals

Cyclo Therapeutics, Inc.

Gold Resource

Rhythm Pharmaceuticals

William Penn Bancorp

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

7 Beaten Down Stocks with Significant Insider Buying

WARRINGTON, Pa., March 29, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates.

Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., March 25, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the closing of its previously announced public offering of 9,230,500 shares of its common stock, par value $0.001 per share, together with warrants to purchase up to 9,230,500 shares of its common stock.

Windtree Therapeutics Announces Closing of $30.0 Million Public Offering

WARRINGTON, Pa., March 23, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the pricing of its previously announced public offering of 9,230,500 shares of our common stock, par value $0.001 per share, together with warrants to purchase up to 9,230,500 shares of our common stock.

Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering

WARRINGTON, Pa., March 22, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has commenced an underwritten public offering of its shares of common stock and warrants to purchase shares of common stock.

Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,874,818 to Windtree Therapeutics Inc (NASDAQ: WINT), covering features of the aerosol delivery system for AEROSURF drug delivery device.

Windtree Therapeutics' AEROSURF Drug Delivery Device Secures US Patent

WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third...

Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug.  13, 2020  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the second quarter ended June 30, 2020 and provided key business updates. 

Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher on Wednesday. The company announced the initial European trial sites activated for its AEROSURF Bridging study and a collaboration for a concomitant independent cerebral physiology study.

Why Windtree Therapeutics Shares Are Trading Higher Today

News for Windtree Therapeutics Stock (WINT)